Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reflux Esophagitis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

NCT00579410
View directory record Official record
Conditions
Esophagitis, Inflammation, Gastritis, Abdominal Pain, Heartburn
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

NCT01045096
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Sep 12, 2026, 5:43 PM EDT
Completed No phase listed Observational

Biology in Patients With Reflux Esophagitis

NCT01194323
View directory record Official record
Conditions
GERD
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 12, 2026, 5:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance in Pediatric Population

NCT02320981
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
Interventions
Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year to 18 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT06391177
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 12, 2026, 5:43 PM EDT
Recruiting No phase listed Observational

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06660342
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00255164
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 12, 2026, 5:43 PM EDT
Not listed Not applicable Interventional

Domperidone for Refractory Gastrointestinal Disorders

NCT00777439
View directory record Official record
Conditions
Gastroparesis
Interventions
Domperidone
Drug
Lead sponsor
Arnold, George, M.D.
Individual
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 12, 2026, 5:43 PM EDT
Completed No phase listed Observational

To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use

NCT01306799
View directory record Official record
Conditions
Barrett's Esophagus, Erosive Esophagitis, Gastroesophageal Reflux Disease(GERD)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

NCT02486263
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only
Other
Lead sponsor
Sudarshan Jadcherla
Other
Eligibility
34 Weeks to 60 Weeks
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

NCT05890001
View directory record Official record
Conditions
Non-erosive Reflux Disease, Erosive Esophagitis
Interventions
BLI5100
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
60
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 12, 2026, 5:43 PM EDT
Recruiting No phase listed Observational

Indiana University Gastrointestinal Motility Diagnosis Registry

NCT04506593
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Functional Vomiting, Irritable Bowel Syndrome (IBS), Constipation, Chronic Intestinal Pseudo-obstruction, Fecal Incontinence, Small Intestinal Bacterial Overgrowth
Interventions
no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophagitis
Interventions
Pantoprazole for approximately 9 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 12, 2026, 5:43 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 12, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 12, 2026, 5:43 PM EDT